Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
AUTOR(ES)
Braun, A
RESUMO
The motor and cognitive effects of a selective D-1 dopamine receptor agonist, SKF 39393, were assessed in patients with Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, and torsion dystonia, using a double-blind placebo-controlled design. Over daily doses ranging from 3.2 to 32 mg/kg and treatment intervals extending from one to seven weeks, no consistent changes could be discerned. The contribution of D-1 receptor mediated mechanisms to the pathophysiology of hyperkinetic extrapyramidal disorders remains uncertain.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1032178Documentos Relacionados
- Extrapyramidal Disorders. Journal of Neural Transmission Supplementum 19
- Selective Desulfurization of Dibenzothiophene by Rhodococcus erythropolis D-1
- D1/D2-dopamine receptor agonist dihydrexidine stimulates inspiratory motor output and depresses medullary expiratory neurons
- CSF choline levels in groups of patients with cranial trauma or extrapyramidal disorders.
- Agonist-induced desensitization of dopamine D1 receptor-stimulated adenylyl cyclase activity is temporally and biochemically separated from D1 receptor internalization.
